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Summary In the present studies we have used the RIF-I tumour in C3H mice to try to identify the
mechanism(s) responsible for the enhancement of melphalan (L-PAM) induced tumour cell killing by the 2-
nitroimidazole misonidazole (MISO). Most of this work was done with a single large dose of MISO
(750mgkg-1) given 30min before injection of L-PAM. We found no effect of MISO on the repair of L-
PAM-induced potentially lethal damage (PLD) as measured using an in vitro clonogenic survival assay.
However, we identified three interrelated and competing processes which affect tumour cell killing by L-PAM
subsequent to MISO injection. First, MISO reduces the clearance rate of L-PAM from the blood, an effect
which enhances the cell killing by L-PAM. Second, MISO reduces the body temperature which produces a
significant reduction in L-PAM cytotoxicity. Third, there is an enhancement of L-PAM cell killing by MISO
over and above these two competing processes which is probably a result of the same mechanism by which
cells in vitro are sensitized to L-PAM by pre-exposure to MISO under hypoxic conditions.
Considerable interest has been shown in combining
conventional anti-tumour agents and nitroaromatic
radiation sensitizers, especially the 2-nitroimidazoles.
Of the chemotherapeutic agents tested in mouse
tumour models, the results to date indicate that
misonidazole (MISO) shows its greatest interaction
with the bifunctional alkylating agents cyclo-
phosphamide (CYT), melphalan (L-PAM), and the
nitrosoureas, especially CCNU (1-[2-chloroethyl]-3-
cyclohexyl-l-nitrosourea) (McNally, 1982; Siemann,
1982).
In general, tumour toxicity is enhanced to a
greater degree than is the response of normal
tissues. As a result, Phase I clinical studies of
MISO in combination with CYT and L-PAM are
currently in progress (Rimondi et al., 1982; Klein et
al., 1982; Coleman et al., 1983).
At the present time, the mechanisms for the
chemosensitization of alkylating agents by MISO
remain unclear. Several processes have been
implicated. These include selective killing of
hypoxic cells by MISO, changes in the
pharmacokinetics and/or metabolism of drugs by
MISO, interference with the repair of potentially
lethal damage (PLD) induced by the
chemotherapeutic agent, and a manifestation of the
in vitro chemosensitization obtained by pre-
exposure of cells to MISO under hypoxic
conditions (Brown, 1982; Siemann, 1982).
In the present study we have used the RIF-I
tumour model to investigate the mechanism by
which MISO sensitizes these tumour cells to L-PAM.
Materials and methods
Tumour system
The RIF-l tumour used in the present study is a
non-immunogenic sarcoma in its syngeneic host
(the C3H/Km mouse) and has been developed for
in vivo-in vitro assay (Twentyman et al., 1980). It is
routinely maintained by passage in vitro. Solid
tumours were produced in 3-4 month old female
C3H/Km mice by innoculating 2 x 105 cells in a
volume of 0.05ml into the base of the
gastrocnemius muscle in the right rear leg. Tumour
growth was followed by measuring two leg
diameters at right angles and tumour volume was
estimated from a calibration curve of tumour
weight (- tumour volume) plotted as a function of
the product of the two leg diameters (Twentyman
et al., 1979). Drug treatments were given when the
tumours were 300-600 mg.
Drug treatments
All drug solutions were prepared immediately prior
to injection. MISO (obtained from the US National
Cancer Institute) was dissolved in a sterile saline
solution (0.9% NaCl). L-PAM (Burroughs
Wellcome Co., Research Triangle Park, NC) was
prepared by dissolving 10mg in 1 ml of 95%
ethanol + 5% HCl. It was subsequently diluted to
the required concentration in a 60% solution of
propylene glycol in saline. In the experiments in
which multiple doses of L-PAM were administered,
the same drug preparation procedures were used to
give a concentration of 0.8 mgml-1. Subsequent
dilutions were carried out in saline. Prepared drug
concentrations were varied so that a constant
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injection volume could be used for each drug.
Solutions of MISO (0.03mlg-1 body wt) and L-
PAM (O.Olmlg-1 body wt) were injected i.p. The
L-PAM was kept on ice once prepared. In the
multiple MISO studies, mice were injected with a
single priming dose of MISO (120mgkg-1)
followed by smaller maintenance doses (30mgkg-1)
given at half-hourly intervals for 7h. The L-PAM
was injected 4h after the start of the experiment
and immediately before the 9th MISO maintenance
injection.
Tumour survival assay
The survival of RIF-l tumour cells was determined
by excising tumours at various times, up to and
including 24h, after injecting L-PAM. Three
tumours were combined and used for each data
point. The tumours were minced by high speed
chopping and a single cell suspension prepared by
incubating the tumours for 30min at 37°C with an
enzyme "cocktail" of 0.05% pronase, 0.02% DNase
and 0.015% collagenase in Hank's Balanced salt
solution (HBSS). The resulting cell suspensions
were filtered through a fine, stainless steel screen
(100,u mesh), centrifuged (1500 rpm; 0min) and the
cell pellet resuspended in Waymouth's medium plus
15% foetal calf serum (Waymouth's + 15% FCS).
The density of viable cells was determined by
counting, in a haemacytometer, the number of cells
which excluded trypan blue. Cells were serially
diluted in Waymouth's + 15% FCS and plated
into plastic petri dishes at 3 pre-determined
dilutions per group. After 13 days incubation at
37°C in an atmosphere of Air + 5% CO2 the
dishes were stained with crystal violet and the
number of colonies, with at least 50 cells, counted.
Surviving fractions were calculated as the number
of colonies counted, divided by the number of cells
plated, corrected for plating efficiency (survival of
untreated cells, which typically fell in the range 20-
40%).
Bioassay
The possible interaction between L-PAM and
MISO in the blood and its subsequent effect on
survival of RIF-1 tumour cells was investigated by
exposing RIF-1 cells in monolayer to plasma from
drug treated animals. C3H mice were injected with
either saline or MISO and L-PAM in the usual
way. At various times after the L-PAM injection
the mice were bled by cardiac puncture under
diethyl ether anaesthesia. The blood from 4-5
animals was combined, and the plasma obtained by
centrifugation (3000rpm; 5min) of heparinized
whole blood. The plasma was diluted by 50% with
serum from mice injected with only the drug
solvents and 2.0ml was then transferred to 60mm
petri-dishes containing RIF-1 tumour cells. These
cells had been plated at a concentration of
1 x 106cells/dish, at least 3 h before exposure to the
plasma, to allow them sufficient time to attach to
the plastic surface. After incubating with the
plasma for 2h (37°C; Air + 5% C02) the plates
were rinsed once with sterile saline, exposed to
0.05 % trypsin (Omin at 37°C) and survival of the
subsequent single cell suspension assayed as
outlined earlier.
In two experiments the MISO was not injected
into the L-PAM treated mice. In the first instance
it was given to mice which were injected with only
the L-PAM solvent and the plasma from both
MISO and L-PAM treated mice mixed immediately
before addition to RIF-1 tumour cells in culture.
Secondly, the MISO was not metabolized by the
mice at all. Instead it was prepared in saline,
diluted with untreated mouse plasma and mixed
with L-PAM treated plasma just before exposure to
the RIF-1 cells. In all conditions the total volume
of plasma added to the plates and the volume of L-
PAM containing plasma remained constant.
Measurement ofplasma drug levels
Plasma was obtained as described earlier and stored
at -20°C. Drug concentrations were analysed by
reversed phase high-performance liquid
chromatography (HPLC).
L-PAM concentration L-PAM blood concentrations
were determined by the procedure described by
Furner et al. (1976). The plasma sample was
diluted (9:1 v/v) with Dansyl proline (150ygml -
in Methanol) which served as an internal standard.
This solution was mixed in the ratio of 11:9 (v/v)
with a deproteinizing agent (10% perchloric acid in
methanol + 0.1% acetic acid). The resulting
solution was vortexed for 15 sec and centrifuged
(3000rpm; 8min). The supernatant was removed
and mixed with KH2PO4 (2:1; v/v) to precipitate
the perchlorate. Following a further vortexing and
centrifugation the supernatant was removed and
passed through a BONDAPAK C18 column
(3.9mm x 30cm). The eluent consisted of 52%
methanol + 1% acetic acid. Drug levels were
measured with a UV detector (Model 450 variable
wavelength detector) at 254nm. Results were
collected on a data module chart recorder.
Quantitation of drug concentration was by peak
area with reference to linear calibration curves. The
columns, detector and chart recorder were all
purchased from Waters Associates, Milford, Mass.
Throughout the preparation procedure all solutions
were kept at 4°C.
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determine MISO blood levels was based on the
procedure described by Workman et al. (1978).
Essentially the plasma was initially diluted (1:1,
v/v) with an internal standard. In this instance this
was the compound Ro 07-0741 (1-(2-nitroimidazol-
l-yl)-3-fluropropan-2-ol; 10pgml-l in methanol).
Samples were then vortexed for 15sec, centrifuged
(3000 rpm; 10min) and the resulting supernatant
run on a RCM-100 (Radial Compression Module)
with a Radial-PAK C18 cartridge (10y,
8mm x 1Ocm). The eluent was 30% methanol and
the drug levels were measured at 324nm. Drug
concentrations were determined as described above.
In vitro temperature studies
The effect of temperature on L-PAM toxicity was
investigated by exposing RIF-1 tumour cells in
monolayer culture to various L-PAM con-
centrations at either 37.0°C, 35.5°C, or 32.0°C.
Exponentially growing tumour cells were plated in
full growth medium at different cell concentrations
(between 102 to 105 cells/petri dish) depending on
the expected survival level, and incubated at 37°C
in an atmosphere of Air + 5% CO2 for 2h to
allow the cells time to attach to the plastic surface.
These cells were then incubated for one additional
hour at the temperature at which the drug
exposures would be carried out. After this time the
medium was removed by aspiration, 2.5ml of the
appropriate drug concentrations added and the
plates returned to the required temperature. At
various times the drug solutions were removed, the
plates washed once with sterile saline and fresh
media added. All the plates were returned to the
37°C incubator for 13 days before assaying for
colony formation in the usual way.
Temperature measurements
Body temperatures were determined using a rectally
inserted thermocouple (Baily Instruments, Saddle
Brooke, NJ 07662). Tumour temperatures were
measured by inserting a microprobe thermocouple
(Baily Instruments) into the tumour of restrained
unanaesthetised mice.
Analysis ofdata
For all survival results, individual data points from
at least 3 experiments are shown. The curves are
the "best-fit" by eye to the data. Where
enhancement ratios (ER's) are quoted, these are the
average values from the survival curves down to a
surviving fraction of 10-3. The ER is defined as the
ratio of drug concentration for L-PAM alone to
that obtained with L-PAM and MISO at the same
survival level. The lines of "best-fit" for the
pharmacokinetic data were determined by linear
B
regression analysis in the regions where exponential
decays operated. Drug half-lives (with 95%
confidence limits) were calculated from these lines.
Results
Tumour cell survival studies
Mice bearing RIF-I tumours were injected with
MISO (750mgkg-1) or saline 30min before various
single doses of L-PAM. Tumours were excised 24h
after the L-PAM injection and cell survival assayed.
The results are shown in Figure 1. Increasing doses
of L-PAM caused increasing amounts of cell kill.
MISO alone at the dose used had no effect on
survival but it did enhance the cytotoxicity of L-
PAM. Although there was some variability between
experiments so that overlap in the data points was
seen, the MISO+L-PAM treatment groups were
always lower than the L-PAM-only groups within
each experiment. The data shown in Figure 1
suggest that MISO had a dose modifying effect for
all L-PAM doses, giving a mean enhancement ratio
(ER) of 1.4.
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Figure 1 The effect of MISO on the response of the
RIF-1 tumour to L-PAM as measured by tumour
survival, assayed 24h after drug administration: (A)
MISO (750mgkg-1) - 30min - L-PAM diluent; (0)
Saline - 30min - L-PAM; (0) MISO (750mgkg-1) -
30min - L-PAM. Individual data points from 4
separate experiments are shown.308 M.R. HORSMAN et al.
Figure 2 shows the effect on survival of varying
the time of removal of tumours from the animals
following an L-PAM injection. When mice were
given saline 30min before a single injection of L-
PAM (8mgkg-1) significant toxicity was seen even
when the tumours were removed within 2h
following the L-PAM dose. Survival continued to
decrease with a nadir being reached at 4-6h. This
was followed by repair of L-PAM induced
potentially lethal damage (PLD), shown by an
increasing surviving fraction. MISO (750mgkg-1)
alone had little or no effect on tumour cell survival
over the 24h period of study. However, it
potentiated the effect of L-PAM. The degree of
enhancement increased with time, with the
maximum effect being observed at 6h. No further
increase in killing was seen and for the remaining
time period the L-PAM alone and the L-PAM with
MISO curves were parallel, suggesting little or no
effect on the repair of PLD.
In order to investigate this further, curves similar
to those shown in Figure 2 were produced for 5
different L-PAM concentrations (2, 4, 6, 8, and
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10mgkg-1) with or without MISO (750mgkg-1).
From these data the lowest survival level attained
with each L-PAM concentration was determined,
regardless of the time at which it occurred.
Generally, however, the results were similar to
those in Figure 2, with the nadir being reached at
4-6h. These values are plotted in Figure 3, as a
function of the difference between the nadir level
and survival at 24h (an indication of the total
amount of PLD repair occurring). Although in
every instance a greater amount of cell killing was
achieved when MISO was given with L-PAM than
for L-PAM alone, no difference is seen between the
L-PAM data and the L-PAM and MISO values.
This confirms that MISO has no effect on L-PAM-
induced PLD repair in the RIF-1 tumour.
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Figure 2 Survival of RIF-1 tumour cells as a function
of time after drug administration: (A) MISO
(750 mgkg-1) - 30min
- L-PAM diluent; (0) Saline
30min - L-PAM (8 mgkg-1); (0) MISO
(750mgkg-1) - 30min - L-PAM (8mgkg-1). The
results from 3 experiments are shown.
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Figure 3 Relationship between the maximum amount
of cell killing obtained and the degree of repair.
Curves similar to those shown in Figure 2 were
produced for different L-PAM concentrations +
MISO and both the lowest level of survival reached
J and the degree of recovery (repair factor) were
28 determined: (0) Saline - 30min - L-PAM; (-) MISO
(750mgkg-1) - 30min - L-PAM. Data from 3
different experiments are shown.
Pharmacokinetic studies
Figure 4 shows plasma levels for both MISO and
L-PAM as a function of time following injections
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Figure 4 Plasma levels of MISO (a) and L-PAM (b) in tumour-bearing C3H mice as a function of time after
L-PAM administration: (A) MISO (750mgkg-1) - 30min - L-PAM diluent; (0) Saline- 30min - L-PAM
(8mgkg-1); (0. A) MISO (750mgkg-1) - 30min - L-PAM (8mgkg-1). Each point represents the plasma
level from one mouse, with the results of 3 separate experiments shown.
of either saline or MISO (750mgkg-1) 30min
before L-PAM (8mgkg-1). A peak level for MISO
occurs 30min after an injection of L-PAM or L-
PAM solvent (Figure 4A). This is followed by a
gradual decline with an elimination half-life of
- 5h. The presence of L-PAM does not alter the
peak MISO level or the clearance rate. However,
MISO (750mgkg-1) given 30min before a dose of
8mgkg-1 L-PAM slowed the rate of clearance of
L-PAM from the blood (Figure 4B). The
elimination half-life of L-PAM was extended from
38.3min (32.7-46.1) to 86.6min (75.3-101.7). This
dose of MISO had no effect on the peak plasma
level of L-PAM.
The effect of MISO on L-PAM pharmacokinetics
was also studied using survival of RIF-tumour cells
grown in monolayer culture as the end point. The
results are shown in Figure 5. Plasma was removed
at various times from mice given either saline or
MISO (750mgkg-1) 30min before L-PAM
(8mgkg-1). Following dilution (1:1) with plasma
from mice given only the drug solvents it was
transferred to the RIF-1 cells in culture. Figure 5
shows that with a 2h exposure to the plasma,
significant cell killing was seen as early as 30min
after injecting the L-PAM. Cell killing decreased as
time in the mouse increased, with the cytotoxicity
being lost by 4h. When MISO was given 30min
before L-PAM an enhancement of the L-PAM
induced killing was obtained. These data correlate
well with the result in Figure 4B.
In order to test for any possible interaction at the
cellular level, plasma from mice receiving MISO
alone was therefore combined with plasma from
mice receiving L-PAM alone and added to the RIF-
1 cells in vitro. As shown in Figure 5, there was no
effect of mixing the drugs after metabolism in the
mice. Similar results are seen even if the MISO was
not metabolized in the mice, but instead prepared
and added to the L-PAM directly. In this
experiment the MISO concentration added was
equivalent to the concentrations in the blood at the
various times of assay (values taken from Figure
4A).
Relationship between pharmacokinetic changes and
increased cytotoxicity
Figure 4B shows that a large single dose of MISO
(750mgkg-1) increases the elimination half-life of
L-PAM (8mgkg-1). In order to see if this change
in L-PAM pharmacokinetics was responsible for
the enhanced cytotoxicity produced by MISO, the
increased half-life was duplicated by giving mice the
same initial dose of L-PAM (8mgkg-1) followed
by subsequent smaller L-PAM doses at hourly
intervals for 6h (see legend of Figure 6 for values).
Identical groups of mice were given the same
priming dose of L-PAM but followed by doses
above or below that simulating the pharmacokinetic
changes produced by MISO. The pharmacokinetic
data on a linear plot are shown in Figure 6. These
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Figure 5 Survival of RIF-1 tumour cells in monolayer culture after a 2h exposure to plasma from tumour-
bearing C3H mice receiving the following: (V) no drugs; (0) Saline - 30min - L-PAM (8mgkg-1); (@)
MISO (750mgkg-1) - 30min - L-PAM (8mgkg-1); ([1) MISO (750mgkg-1); (A) MISO (750mgkg-1) or
L-PAM (8mgkg-1) - plasma combined before addition to cells in culture; (A) L-PAM (8mgkg-1) only -
plasma mixed with unmetabolized MISO before exposure to cells; (0) no drugs - plasma combined with
unmetabolized MISO before addition to cells in culture. Three separate experiments are shown with each
point representing the survival of cells from a single plate having received diluted serum pooled from 4-5
mice.
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Figure 6 Curves of plasma L-PAM concentration as a function of time after injection. Panel (a) shows the
mean curves from 4 different experiments for L-PAM only (8mgkg-1, 0) and L-PAM preceded by MISO
(750mgkg-1, 0). Panels (b) and (c) show the mean plasma concentration versus time curves for mice given
the same initial L-PAM dose (8mgkg-1) followed hourly for 6h with smaller L-PAM doses. These L-PAM
doses are designated X/2 (O); X (A); 3/2X (O); and 2X (V), where X is the attempt to simulate the
MISO+L-PAM curve in panel a (shown by the dashed line in panels b and c), and was obtained by injecting
2.5, 1.3, 0.7, 0.7, 0.7 and 0.56mgkg-1 at 1, 2, 3, 4, 5 and 6h respectively. The pooled data from 2 to 3
separate experiments are shown, with each point representing the mean plasma level from one mouse. Lines
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results are the mean values for 3 to 4 separate
experiments. For each individual experiment the
area under the curve (AUC) was determined by
weighing the cut-out area of graph paper. Taking
the AUC for the single dose of L-PAM (8mgkg-1)
as 1.0, we determined the factor by which the AUC
for each treatment schedule was increased. Tumour
survival, assayed 24h after the L-PAM priming
dose for each injection regimen, was also measured
in each experiment and the ER for cell survival
calculated from the L-PAM dose-response curve
(Figure 1). The results for both the increase in the
AUC and the enhancement of tumour cell killing
following a single dose of L-PAM, by either the
multiple L-PAM dose regimen or the large single
injection of MISO 30 min before L-PAM, are
shown in Figure 7. Increasing the AUC by either
method increased cell killing. However, the
enhancement in tumour cell kill for a given increase
in AUC was greater for the multiple L-PAM
groups than for the MISO and L-PAM groups
(ERs of 2.1 and 1.4, respectively, for the same
AUC increase).
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Figure 7 Relationship between the change in L-PAM
pharmacokinetics and increased tumour cytotoxicity:
closed symbols, MISO (750mgkg-1) 30min - L-
PAM (8mgkg- ); open symbols, Saline - 30min
L-PAM (8 mgkg-1), followed by various smaller
L-PAM doses at hourly intervals for 6h as explained
in Figure 6: (0) saline; (EJ) X/2; (A) X; (O) 3/2X;
(7) 2X. The factor increase in AUC is the increase in
area of the data shown in Figure 6, taking the AUC
for the single dose of L-PAM as 1.0. Enhancement of
survival was measured by an excision assay performed
24h after drug administration. The data points are
from 2 to 4 separate experiments with the lines
showing the "best-fit" to the data by eye.
Changes in tumour and body temperature
A large single dose of L-PAM (8mgkg-1) caused a
drop in rectal temperature of about 4°C in C3H
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Figure 8 Mouse body temperature as a function of
time after drug administration: (0) Saline - 30min -
L-PAM diluent; (Cl) MISO (750mgkg-1); (A) MISO
(750mgkg 1) - 30min - L-PAM diluent; (0) Saline -
30min - L-PAM (8mgkg-1); (A) MISO
(750mgkg-1) - 30min - L-PAM (8mgkg-1). The
shaded area represents the body temperature of
untreated mice. Arrows indicate drug injections: t, saline or MISO; ', L-PAM diluent or L-PAM. Each
point represents the mean temperature from three
mice.
mice (Figure 8). This lowered temperature was
reached within one hour after the injection of the
L-PAM, but was followed by recovery such that 8h
later the body temperature had returned to normal.
Most of this effect was due to the L-PAM diluent
(Figure 8). The injection of MISO (750mgkg-1) alone produced a slightly greater fall in body temperature than the L-PAM diluent. However, when MISO preceded L-PAM, the fall in body temperature was greater (6-70C) and more
prolonged: no significant recovery was observed,
even 8h after giving the drugs. Table I shows a comparison between tumour and
body temperatures measured in the same mice.
Temperature recordings were carried out every hour for 6h after injecting the drugs and the mean
values calculated. No significant difference can be
seen between the body and tumour results. This is probably a consequence of the tumours being in a highly vascularized intramuscular site in the mouse
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Table I Comparison between tumour and body
temperatures in C3H mice
Mean body Mean tumour
Treatment temperature (°C) temperature (°C)
Control
(no drugs) 36.9 (36.7-37.00) 36.4 (36.2-36.6)
Saline - 30min -
L-PAM (8mgkg-1) 35.3 (34.8-35.7) 35.3 (34.8-35.7)
MISO (750mgkg-1)
- 30min - L-PAM
(8mgkg-1) 32.1 (31.1-33.0) 32.0 (31.1-32.9)
The body and tumour temperatures from 4 mice per
group were measured every hour for 6h after drug
injections. The mean of these values + 1 s.e. are shown.
leg. These results show that for the RIF-1 tumour
grown in this manner, body temperature is an
accurate indicator of the tumour temperature.
Effect oftemperature on cell killing in vitro
In an effort to see if the change in mouse body
temperature could alter the toxicity of L-PAM in
RIF-1 tumour cells, monolayer cell cultures were
exposed to various L-PAM concentrations at
different temperatures. The results are shown in
Figure 9. The temperatures selected - 32.00, 35.50,
and 37.0°C - were based on the respective mean
body temperatures for MISO and L-PAM, L-PAM
only and controls during the first 6h after injecting
L-PAM (Figure 8). This time period was selected
because the data of Figure 2 suggested that this was
the period over which cell killing occurred. As
illustrated in Figure 9A, a reduction in temperature
in the monolayer culture caused a concomitant
dose-modifying reduction in cell killing by a factor
of 1.8 (35.5°C to 32.0°C) and 2.2 (37.0°C to
32.0°C). The effects of exposure of RIF-1 cells to
1.0pgmlV- L-PAM for various time periods at
different temperatures are shown in Figure 9B. A
plateau level was reached at 4-6h at 32.0°C.
Exposure at 37.0°C gave a similar survival response
although the plateau occurred at a lower level of
survival. This demonstrates that the effects of
temperature on cell killing are not a transitory
result of temperature differences in the rate of
breakdown of L-PAM in vitro.
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Figure 9 The effect of temperature on the survival response of RIF-1 tumour cells in monolayer culture: (0,
*) 32.0°C; (Cl) 35.50C; (A, A) 37.0°C. (a) RIF-I cells exposed to different L-PAM concentrations for 1 h.
(b) RIF-I cells exposed to 1.0ygml'1 L-PAM for different times. Results shown are individual data points
from 2 separate experiments.
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Multiple MISO studies
When mice were injected with a single MISO
priming dose at 120mgkg-1 followed by successive
maintenance doses (30mgkg-1) given every 30min
for 7h, a mean blood level of lI00pgmlP was
obtained (data not shown). The effects of this
regimen on the cytotoxicity and pharmacokinetics
of L-PAM are shown in Figure 10. Whilst MISO
alone had no effect on survival, it did increase the
cell killing by L-PAM with an ER of at least 1.1
(Figure lOA). However, no change in L-PAM
pharmacokinetics was obtained (Figure lOB).
Figure 11 demonstrates the actions of the
multiple MISO schedule on mouse body
temperature. When given in conjunction with a
multiple saline regimen, L-PAM caused a small
drop in body temperature of 2-3°C. The effect was
maximal within 1 h following the L-PAM and
disappeared by 4h. If MISO was injected instead of
the saline an additional 2°C drop was seen with a
return to normal occurring about 6h after injecting
c
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the L-PAM. As seen with the large single MISO
dose (Figure 8) the MISO effect seems to be
primarily due to an interaction between the MISO
and L-PAM diluent.
Discussion
In the present studies we have confirmed previous
reports that a single large dose of MISO
(750mgkg-1) enhances the cytotoxic effects of L-
PAM on tumours in vivo (see review by McNally,
1982). We have shown, however, that this is not the
result of a single mechanism: pharmacokinetic
changes, effects on tumour temperature and a third
phenomenon probably related to hypoxia-
dependent metabolism are all involved.
In our system, with the RIF-l tumour,
enhancement is not the result of selective killing of
hypoxic cells by MISO, since MISO alone has no
effect on tumour cell viability. A number of studies
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Figure 10 The effect of a multiple MISO injection schedule on (a) the tumour response to L-PAM measured
24h after injecting L-PAM, and (b) plasma L-PAM levels: (0) Saline given at half-hourly intervals for 7h
+L-PAM (8mgkg-1); (0) MISO for 7h (a single priming dose of 120mgkg-I followed by 30mgkg- given
at half-hourly intervals for 7h) +L-PAM (8mgkg l). L-PAM was given 4h into the injection schedule. Data
points are from 3 experiments. In panel b each point represents the plasma level from one mouse, with the
line obtained by linear regression analysis.
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Figure 11 The effect of a multiple MISO injection
schedule on mouse body temperature: (0) Saline +
L-PAM diluent; (AL) MISO + L-PAM diluent; (0)
Saline + L-PAM (8mgkg-1); (-) MISO + L-PAM
(8mgkg-1). The shaded area represents the body
temperature of untreated mice. Arrows indicate drug
injections: t, Saline or MISO (an initial dose of
120mgkg-1, followed by subsequent injections of
30mgkg-1); 4, L-PAM diluent or L-PAM. Each
point represents the mean temperatures from 3 mice.
have suggested that the effect of MISO on
alkylating agents involves an inhibition of PLD
repair. This was reported for CYT in RIF-1 (Law
et al., 1981) and WHF1B tumours (Martin et al.,
1981) but not in KHT sarcomas (Siemann &
Mulcahy, 1982). The data of Figure 2 suggest no
inhibition of PLD repair. Similar results have been
reported for MISO in the KHT tumour (Siemann
& Mulcahy, 1982) and for the related 2-
nitroimidazole, Ro 03-8799, in the MT tumour
(Sheldon & Batten, 1982). However, this latter
study demonstrated that the amount of repair was
dependent on the nadir survival level achieved
between 4 to 6h after drug administration (i.e., the
lower the nadir value, the greater the recovery). The
similar PLD repair factors seen in these previous
studies are therefore consistent with some effect on
PLD repair, since the lower nadir in survival in
nitroaromatic-treated groups should have produced
a greater degree of recovery than in the L-PAM
controls. Our data in Figure 3 however show that
MISO has no effect on PLD repair even when the
lower nadir it produces is taken into account.
The large single dose of MISO (750mgkg-1)
used in these experiments did not alter the peak
plasma levels of L-PAM (Figure 4B) but did delay
the plasma clearance. Confirmation of this data
was obtained using survival of RIF-l tumour cells
grown in monolayer culture as the end point
(Figure 5). Several investigators have similarly
reported an increase in the plasma half-life of L-
PAM by MISO (Stephens et al., 1981; Clutterbuck
et al., 1982; Hinchliffe et al., 1983; Lee &
Workman, 1983).
The breakdown of L-PAM in vivo has been
suggested to be primarily by hydrolysis and
alkylation and not by enzymatic biotransformation
(Evans et al., 1982). The pharmacokinetic effect of
MISO may result from an interference with these
processes or some other as yet unknown metabolic
route. Several studies have clearly shown the effect
of MISO on drug metabolism. Lee & Workman
(1983) demonstrated that MISO could inhibit the
hydroxylation of CCNU and possibly inhibited the
subsequent metabolism of the hydroxylated species.
In addition, MISO has been shown to reduce the
clearance of chlorambucil by inhibition of its
mitochondral fl-oxidation to phenyl acetic mustard
(Workman et al., 1983).
One important feature of the present study was
an attempt to quantitate the effect of changes in the
pharmacokinetics of L-PAM in order to answer the
question of whether these alterations could account
for the enhanced tumour cytotoxicity produced by
MISO. We were able to simulate the increased
AUC produced by MISO by giving repeated small
injections of L-PAM and to determine the
subsequent effects on tumour cell killing. Figure 7
shows a summary of the data. The major finding
was that the enhancement ratio for cell killing by
MISO was less than that which should have
occurred as a result of the increased AUC it
produced. Had the pharmacokinetic effect
accounted for the chemosensitization by MISO, an
ER of approximately 2.1 rather than the observed
ER of 1.4 should have been produced. In other
words, MISO appears to be protecting against L-
PAM-induced cytotoxicity.
An explanation for this discrepancy lies in the
temperature drop produced by the MISO dose. As
the in vitro data show (Figure 9), a temperature
drop of only 3.5°C (from 35.5°C to 32.0°C) causes
a dose-modifying reduction in the amount of cell
killing by L-PAM by the factor of approximately
1.8. Since the values of 35.50C and 32.0°C were
respectively the mean tumour temperatures (Table
I) following L-PAM only and MISO + L-PAM
during the first six hours after injecting L-PAM
(the time period over which cell killing occurs) we
would expect this same factor to apply in vivo.
Hence, if only these competing mechanisms were
involved, we would expect the ER produced by thisMISO CHEMOSENSITIZATION: COMPETING MECHANISMS 315
dose of MISO to be 2.1/1.8 or 1.2. In fact, we
observed an ER of 1.4, suggesting that a small
enhancement of L-PAM cytotoxicity by a factor of
1.4/1.2, or 1.2, is produced by MISO at the cellular
level. Our data, which show a small enhancement
of L-PAM cytotoxicity by multiple MISO injections
(ER=1.1) in the absence of any pharmacokinetic
changes (Figure 10), despite significantly lower
temperatures in the MISO treated groups (Figure
11), support this conclusion.
A likely candidate for this effect at the cellular
level is the in vitro preincubation effect, by which
exposure of cells in vitro to MISO under hypoxic
conditions increases their sensitivity to subsequent
exposures to L-PAM and certain other
chemotherapeutic drugs (Roizin-Towle & Hall,
1978; Stratford et al., 1980; Taylor et al., 1983).
Taylor et al. (1983) have demonstrated that this
effect is a result primarily of an increased efficiency
of DNA interstrand cross-link formation, and
secondarily of a depletion of intracellular
glutathione levels. We have data which show no
loss of glutathione levels from the RIF-I tumour
after MISO (1000mgkg-1) injection (Bump,
personal communication), so it is unlikely that this
is a contributing factor to the enhancement seen in
vivo. Thus, we believe that the enhancement of L-
PAM cytotoxicity by MISO seen when the
pharmacokinetic and temperature effects are
accounted for, or eliminated, is probably a
manifestation of the hypoxia-mediated enhancement
of DNA interstrand cross-links observed in vitro.
In conclusion, we have identified three processes
which modify the response of tumours in vivo to L-
PAM given after a large single dose of MISO. First
there is an increase in the exposure of cells to L-
PAM (increase in AUC of L-PAM vs time plot)
produced by a slowing of the breakdown and
elimination of L-PAM from the plasma. This
enhances the cytotoxicity of L-PAM. Second, MISO
produces a significant fall in the body temperature,
which reduces the tumour cell killing by L-PAM,
probably by inhibiting the temperature-dependent
cellular uptake of L-PAM (Begleiter et al., 1979).
Third, there is an effect of MISO which appears to
be a manifestation of the hypoxia-mediated in vitro
preincubation effect. The fact that these phenomena
are competing and that the magnitude of each is
likely to be dependent on the MISO and
chemotherapeutic drug dose, the mouse strain, and
the tumour type, provides a ready explanation for
the disagreement in the literature as to the
magnitude and significance of chemosensitization
by MISO in vivo. However, at clinically relevant
MISO levels in which the pharmacokinetic and
temperature effects are all but eliminated,
chemosensitization can still be obtained. This has
been reported by us and by others (Brown & Hirst,
1982; Twentyman & Workman, 1983), suggesting
that the combination of nitroaromatic
radiosensitizers and chemotherapeutic drugs may
have a clinical role to play.
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